Inhaler
Top in allergy/asthma: Price cap on inhaler products; NIH grant for Cincinnati Children's
The Allergy & Asthma Network praised three major pharmaceutical companies, AstraZeneca, Boehringer Ingelheim and GSK, that announced they will enact a $35 price cap on their inhaler products.
Allergy & Asthma Network says $35 inhaler price cap will improve health, wellness
After three major pharmaceutical companies said they will enact a monthly $35 price cap on their inhaler products, the Allergy & Asthma Network applauded this move to make treatment more affordable for patients.
Major pharmaceutical companies put $35 monthly price cap on asthma inhalers
Three of the largest producers of asthma inhalers have agreed to cap the price of their inhaler products at $35. This comes after several Democratic lawmakers asked pharmaceutical companies to decrease the prices of inhalers.
Tertiary care center providers prescribe ‘select agents’ in asthma inhalers
WASHINGTON —Tertiary care center providers generally reported similar asthma inhaler practices despite being from different disciplines, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Top in allergy/asthma: Phone screen protector triggers allergy; Q&A on Flovent generics
After a woman developed a rash on her face and fingers several times, her doctors discovered the cause was her cell phone, specifically the acrylate screen protector on her cell phone.
Q&A: Asthma patients have options as GSK moves Flovent to generic production
GSK has stopped manufacturing its Flovent HFA and Flovent Diskus fluticasone propionate inhalers for asthma and has made authorized identical generic versions of these devices available instead.
Most-read FDA actions from 2023 in pulmonology
Healio Pulmonology has compiled the top news from the FDA posted in 2023.
Reliever inhalers used more on days with high wildfire-related air pollution
ANAHEIM, Calif. —Patients with asthma used reliever inhalers more on days with unhealthy air quality during the Canadian wildfires, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Canadian wildfires increase asthma reliever use by almost 500%
ANAHEIM, Calif. — The wildfires in Canada in May and June 2023 were associated with short-term increases in asthma reliever use, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Digital inhaler data help identify reliever medication overuse, predict exacerbations
HONOLULU — Analyzing real-world digital inhaler data using expert-consensus thresholds on reliever medication use helped find medication overuse and may predict exacerbations, according to an abstract presented at the CHEST Annual Meeting.